Skip to main content

MedPath Trial Home

Organizations News Research

Data Sources:ClinicalTrials.govEU CTRFDAEMANMPATGAHealth CanadaWHO ICTRP

MedPath Trial Home

Search trials. Track pipelines. Understand approvals. With AI-powered intelligence for clinical research.

Product

Clinical Trials
Drug Intelligence
Global Approvals
AI Research
Pricing

Resources

FAQ
Search

Company

News
About
Contact

Legal

Privacy Policy
Terms of Service

Disclaimer: This website provides information retrieval and data analysis services. The content does not constitute medical advice. Eligibility assessments are for reference only and should not replace consultation with qualified healthcare professionals. Data is sourced from public registries and regulatory agencies; MedPath does not guarantee completeness or accuracy. Always verify information with primary sources.

© 2026 MedPath Trial. All rights reserved.

We value your privacy

We use cookies to analyze site traffic and improve your experience. See our Privacy Policy.

BAYER AUSTRALIA LTD

Home Clinical Trial Sponsors and OrganizationsBAYER AUSTRALIA LTD

BAYER AUSTRALIA LTD

500 Wellington Road, Mulgrave, Victoria, Australia

Also known as:

bayer crop

Share to Twitter Share to Facebook Share to LinkedIn Share to Reddit

Clinical Trials

6

0 active

Approvals

474

Total approvals

Agencies

2

Regulatory bodies

Founded

N/A

Overview

Trial Phase Distribution

Phase

Trials

Share

Phase 3

4

66.7%

Phase 2

2

33.3%

Trial Status Distribution

Completed

6

100.0%

Clinical Trials

Trials sponsored by this organization (6)

A clinical study to determine the safety and efficacy of gadobutrol 1.0 molar (Gadovist 'Registered trade mark') in comparison to ProHance 'Registered trade mark' (gadoteridol) 0.5 molar in patients referred for contrast-enhanced Magnetic Resonance Imaging (MRI) of the central nervous system.

Sep 2008402 participants

A phase III randomised, placebo-controlled study of Sorafenib in repeated cycles of 21 days in combination with paclitaxel / carboplatin chemotherapy in patients with unresectable stage III or IV melanoma.

Oct 2005250 participants

A Phase III randomised study of BAY 43-9006 in patients with unresectable and/or metastatic renal cell cancer

Oct 2005884 participants

A Phase III randomized, placebo-controlled study of sorafenib in patients with advanced hepatocellular carcinoma

Oct 2005602 participants

Once-daily oral direct factor Xa inhibitor BAY 59-7939 in patients with acute symptomatic deep-vein thrombosis. The Einstein-DVT dose-finding study.

Oct 2005520 participants

Oral Direct Factor Xa Inhibitor BAY 59-7939 in Patients with acute symptomatic Deep Vein Thrombosis. A phase II dose finding and proof of principle trial.ODIXa-DVT

Oct 2005600 participants

Approvals

Approvals by Agency

NMPA

National Medical Products Administration

6

Approvals

TGA

Therapeutic Goods Administration

468

Approvals

Recent Approvals

Rennie Spearmint Flavour (517726)

Rennie Spearmint Flavour (517726)

Berocca Hydrate effervescent tablets grapefruit flavour (512654)

Berocca Hydrate effervescent tablets grapefruit flavour (512654)

Berocca Energy Effervescent Tablet Strawberry Flavour (508474)

Berocca Energy Effervescent Tablet Strawberry Flavour (508474)

Berocca Energy Effervescent Tablets Variety Pack (4x15 effervescent tablets new formulation) (496982)

Berocca Energy Effervescent Tablets Variety Pack (4x15 effervescent tablets new formulation) (496982)

Berocca Energy Effervescent Tablets Raspberry Blackcurrant Flavour (493008)

Berocca Energy Effervescent Tablets Raspberry Blackcurrant Flavour (493008)

News

No news articles found

On this page

Overview
Clinical Trials6
Approvals474
News

Back to Organizations